Skip to main content
. 2014 Oct 27;9(10):e111336. doi: 10.1371/journal.pone.0111336

Figure 4. Colitis-associated tumor development is increased in transgenic mice overexpressing LMα1.

Figure 4

(A) Schematic overview of the AOM/DSS and of the cyclic DSS protocols. (B) Control and transgenic mice treated with AOM/DSS or with cyclic DSS develop different types of lesions among them dysplasia and in situ carcinomas that were quantified. Tg-lama1 animals develop more tumors than controls when submitted to the treatments (n = 7, *p<0.05 for AOM/DSS; n = 7, *p<0.05 for cyclic DSS). (C) Dysplasia and an in situ carcinoma are shown by hematoxylin-eosin staining (HE). Glands in these lesions are strongly positive for LMα1 (red), LMα5 (green, lower panels) and present nuclear p53 (green, middle panels). Nuclei were visualized with DAPI. e: epithelial cells; m: muscle; c: cancer cells; s: stroma; arrows: BM area. Scale bars: 50 µm.